Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) obtained approval to export tirzepatide as an active pharmaceutical ingredient (API) to the European Union, according to a Thursday filing with the Shanghai Stock Exchange.
Sinopep-Allsino's factory in Lianyungang passed the EU's good manufacturing practice compliance for export, the filing said.
Tirzepatide is indicated for type 2 diabetes.